Abstract
78TiP Phase Ib/IIa safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have